Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine –possible therapeutic implication

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19. Until now, diverse drugs have been used for the treatment of COVID-19. These drugs are associated with severe side effects, e.g. induction of erythrocyte death, named eryptosis. This massively affects the oxygen (O(2))...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghashghaeinia, Mehrdad, Dreischer, Peter, Wieder, Thomas, Köberle, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781621/
https://www.ncbi.nlm.nih.gov/pubmed/33305655
http://dx.doi.org/10.1080/15384101.2020.1859197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781621/
https://www.ncbi.nlm.nih.gov/pubmed/33305655
http://dx.doi.org/10.1080/15384101.2020.1859197

Ejemplares similares